[Skip to Content]
[Skip to Content Landing]
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

To the Editor: Dr Mukherjee and colleagues1 warned of the possibility of increased CV events associated with selective COX-2 inhibitors, based on the results of 2 long-term (6-9 months) safety studies in rheumatoid arthritis (RA) patients with celecoxib 800 mg (CLASS) and rofecoxib 50 mg (VIGOR).2,3

First Page Preview View Large
First page PDF preview
First page PDF preview